The US IBD market is estimated to grow significantly at a CAGR of around 4.7% during the forecast period. factors such as the significant prevalence of IBD such as Crohn’s disease and ulcerative colitis across the country. As per the Centers for Disease Control and Prevention (CDC), the prevalence of Crohn’s disease and ulcerative colitis in the US was 201 and 238 per 100,000 population respectively in 2015. Moreover, the CDC also estimates the incidence rate of types of IBD across the country. As per the CDC, the incidence of Crohn’s disease and ulcerative colitis were nearly 14.6 and 14.3 per 100,000 population respectively in 2015. Additionally, according to the aforementioned organization, the percentage of people diagnosed with IBD (either Crohn’s disease or ulcerative colitis) increased from 0.9% of US adults in 1999 to 1.3% of US adults in 2015. This percentage is further expected to expand in the near future; thereby, promising significant growth for the IBD market during the forecast period.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/us-ibd-inflammatory-bowel-disease-market
US IBD market is segmented on the basis of disease type, diagnostics, and therapeutics. US IBD market is segmented on the basis of disease type into ulcerative colitis and Crohn’s disease. Crohn’s disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn’s disease than ulcerative colitis. On the basis of diagnostics, the market segmented into blood and stool, endoscopies, ultrasound, and X-rays. Endoscopy is a conventional diagnostic method that is widely being used for the diagnosis of IBD and having a considerable share in the market. The therapeutics segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/us-ibd-inflammatory-bowel-disease-market
The companies which are contributing to the growth of the US IBD market include Abbott Laboratories, AbbVie Inc., Accesa Labs, Celgene Corp., Eli Lilly and Co., Johnson & Johnson Services Inc., Laboratory Corporation of America Holdings, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.
Market Segmentation
US IBD Market by Disease Type
- Ulcerative Colitis
- Crohn’s Disease
US IBD Market by Diagnostics
- Blood and Stool Tests
- Endoscopies,
- Ultrasound
- X-Ray
US IBD Market by Therapeutics
- Surgery
- Anti- Inflammatory Drug Administration
- Steroids
- Immunosuppressant
- Biological Drugs
- Amino salicylates
- Others
Company Profiles
- Abbott Laboratories
- AbbVie Inc.
- Accesa Labs
- Boehringer Ingelheim International GmbH
- Celgene Corp.
- Eli Lilly and Co.
- Johnson & Johnson Services Inc.
- Laboratory Corporation of America Holdings
- Pfizer Inc.
- Sanofi S.A.
- Takeda pharmaceutical Co., Ltd.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
